Ultrahypofractionated SBRT Prostate Cancer Radiotherapy Does Not Increase Radiotoxicities
Ultrahypofractionated SBRT can deliver radiotherapeutic doses in 2 weeks or fewer without increasing toxicity risk, according to findings from PACE-B.
Prostate Cancer
PROSTATE CANCER ADVISOR
FEATURED CONTENT
-
-
FDA Proposal Threatens Transparency on Cancer Drug Safety and Efficacy
FDA documents have been a trove of information for researchers, leading to new insights about the safety and efficacy of a drug. An FDA proposal could end that. -
Everyone’s Conflicted: How Open Payments Did Little to Discourage Conflicts of Interest in Oncology
Since its inception, the Open Payments act does not appear to have prompted physicians to accept fewer payments from industry overall. -
The Disappointing Reality of Crowdfunding Cancer Care
If crowdfunding doesn’t work, here’s how oncologists can help patients with financial toxicity. -
Some Targeted Therapies May Miss the Mark
Ten different drugs continued to kill cancer cells even when their target proteins were removed.
Current Research Into Pain Assessment
Immunotherapy for Prostate Cancer
Targeted Agents
Targeted Agents (cont.)
Radium-223
Chemotherapy
Immunotherapy
Treatment Sequencing
Androgen Deprivation Therapy
Duration of ADT
Docetaxel in Combination With ADT
HSD3B1 Allele Inheritance Linked With ADT Resistance
ADT and Radiation
Predictions for the Future
PROSTATE CANCER NEWS
PSA Levels No Different With Exposure to Antidiabetes Meds
Pathogenic, Likely Pathogenic Variants Common in Prostate Cancer
Investigating the Role of Salvage Lymph Node Dissection in Nonmetastatic CRPC
Prostate Cancer Salvage Combo Benefits Confirmed
Prostate Cancer Risk Higher Among Men With IBD
Want to read more?
Please login or register first to view this content.
Next post in Prostate Cancer
